Skip to content

ALSERES PHARMACEUTICALS INC /DE: 10-K filed 2012-03-29

What ALSERES PHARMACEUTICALS INC /DE reported in its annual report filed 2012-03-29 (fiscal FY 2011): 31 published measures, 81 facts as tagged in accession 0001193125-12-139930.

This filing

Form
10-K (annual report)
Filed
2012-03-29
Fiscal period
fiscal FY 2011
Accession
0001193125-12-139930 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ALSERES PHARMACEUTICALS INC /DE filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-31170,729USD
At 2010-12-31460,592USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-12-3130,424,508USD
At 2010-12-3142,318,715USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-31-30,602,223USD
At 2010-12-31-47,286,281USD
At 2009-12-31-42,442,403USD
At 2008-12-31-40,013,361USD
At 2007-12-31-22,414,471USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-31135,843USD
At 2010-12-3198,514USD
At 2009-12-31314,964USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,882,214USD365
1992-10-16 to 2011-12-31-197,046,068USD7016
2010-01-01 to 2010-12-31512,419USD365
2009-01-01 to 2009-12-31-10,776,937USD365
2008-01-01 to 2008-12-31-20,847,459USD366
2007-01-01 to 2007-12-31-19,548,348USD365
1992-10-16 to 2006-12-31-143,503,529USD5190

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,484,803USD365
1992-10-16 to 2011-12-31-159,402,322USD7016
2010-01-01 to 2010-12-31-2,950,667USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,373USD365
1992-10-16 to 2011-12-311,654,487USD7016

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
1992-10-16 to 2011-12-31900,000USD7016

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,220,744USD365
1992-10-16 to 2011-12-31159,631,320USD7016
2010-01-01 to 2010-12-312,699,200USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31301,388USD365
1992-10-16 to 2011-12-31-93,155USD7016
2010-01-01 to 2010-12-3135,017USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-12-31-197,048,068USD
At 2010-12-31-194,165,854USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-01-01 to 2011-12-3129,626,072shares365
2010-01-01 to 2010-12-3126,686,933shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2011-01-01 to 2011-12-3129,626,072shares365
2010-01-01 to 2010-12-3131,586,933shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-0.1USD/shares365
2010-01-01 to 2010-12-310.01USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-0.1USD/shares365
2010-01-01 to 2010-12-310USD/shares365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-312,475USD
At 2010-12-3147,674USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-1,565,070USD365
1992-10-16 to 2011-12-31-195,541,835USD7016
2010-01-01 to 2010-12-31-3,122,937USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-31168,254USD
At 2010-12-31208,750USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,838,484USD365
1992-10-16 to 2011-12-3114,489,110USD7016
2010-01-01 to 2010-12-312,643,630USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-3130,424,508USD
At 2010-12-3142,288,212USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2011-01-01 to 2011-12-3118,256USD365
1992-10-16 to 2011-12-3126,356USD7016
2010-01-01 to 2010-12-318,100USD365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,565,070USD365
1992-10-16 to 2011-12-31196,441,835USD7016
2010-01-01 to 2010-12-313,122,937USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3130,635,720shares
At 2010-12-3126,785,645shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-12-31-31,367USD
At 2010-12-310USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-12-314,965USD
At 2010-12-3114,073USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,913,581USD365
2010-01-01 to 2010-12-31512,419USD365
2009-01-01 to 2009-12-31-10,776,937USD365
2008-01-01 to 2008-12-31-20,856,769USD366
2007-01-01 to 2007-12-31-19,539,038USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-2,882,214USD365
2010-01-01 to 2010-12-31143,137USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,032,946USD365
1992-10-16 to 2011-12-3168,814,888USD7016
2010-01-01 to 2010-12-312,657,488USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-12-3140,751USD365
1992-10-16 to 2011-12-312,890,666USD7016
2010-01-01 to 2010-12-3158,598USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-01-01 to 2011-12-3143,814USD365
1992-10-16 to 2011-12-31-1,474,064USD7016

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
1992-10-16 to 2011-12-3166,731,339USD7016

Inspect the source

Entity
ALSERES PHARMACEUTICALS INC /DE / CIK 0000094784
Captured
SEC response SHA-256
67d3a858977a656ee0b8fc871dfd3b585faeffaf3905b0040597f843e1ed1a76

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000094784.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))